Table 1 Proangiogenic in vitro effects of different sEV samples.

From: Serum-derived extracellular vesicles (EVs) impact on vascular remodeling and prevent muscle damage in acute hind limb ischemia

sEVs

Angiogenesis assay %

Proliferation assay %

Average %

Results

1

42.8 ± 1.4

62.5 ± 2.3

52.6 ± 1.9

e-sEV

2

54.4 ± 3.9

56.4 ± 3.1

55.4 ± 3.5

e-sEV

3

31.9 ± 1.4

89.5 ± 0.5

60.7 ± 1.0

e-sEV

4

53.3 ± 0.3

64.1 ± 1.1

58.7 ± 0.7

e-sEV

5

68.7 ± 2.6

55.5 ± 3.1

62.1 ± 2.9

e-sEV

6

43.8 ± 0.9

77.6 ± 4.0

60.7 ± 2.5

e-sEV

7

88.5 ± 4.2

66.2 ± 3.3

77.4 ± 3.8

e-sEV

8

65.5 ± 0.6

44.4 ± 0.5

54.9 ± 0.6

e-sEV

9

56.5 ± 4.5

50.1 ± 3.9

53.3 ± 4.2

e-sEV

10

31.5 ± 1.1

99.8 ± 5.6

65.7 ± 3.4

e-sEV

11

35.2 ± 8.3

8.5 ± 4.1

21.9 ± 6.2

i-sEV

12

99.2 ± 0.5

32.2 ± 3.4

65.7 ± 2.0

e-sEV

13

28.8 ± 3.2

24.5 ± 2.3

26.7 ± 2.8

i-sEV

14

41.7 ± 6.6

68.6 ± 4.5

55.2 ± 5.6

e-sEV

15

50 ± 3.8

55 ± 4.9

52.5 ± 4.4

e-sEV

16

8.3 ± 1.3

19.1 ± 4.0

13.7 ± 2.5

i-sEV

17

66.7 ± 4.5

41.1 ± 4.2

53.9 ± 6.6

e-sEV

18

15.1 ± 1.5

3.6 ± 0.6

9.5 ± 2.6

i-sEV

  1. 18 sEV samples evaluated by in vitro angiogenesis assay and in vitro proliferation assay on ECs. The average represents the mean value of results of both assays ± SD (see Methods). sEVs with an average value exceeding 50% have been considered effective sEVs (e-sEVs) otherwise they are ineffective (i-sEVs).
Back to article page